IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Postmarketing surveillance study of benazepril in Chinese patients with hypertension: An open-label, experimental, epidemiologic study
Lu, J; Lee, LM; Cao, WH; Zhan, SY; Zhu, GY; Dai, LQ; Hu, YH
关键词adverse effects angiotensin-converting enzyme inhibitors cough hypertension product surveillance postmarketing
刊名CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
2004-05-01
65期:3页:300-319
收录类别SCI
文章类型Editorial Material
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental ; Pharmacology & Pharmacy
研究领域[WOS]Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]BLOOD-PRESSURE ; INTERNATIONAL-SOCIETY ; METAANALYSIS ; MANAGEMENT ; PATTERNS ; TRIAL ; MASS ; AGE
英文摘要

Background: Benazepril hydrochloride is an angiotensin-converting enzyme inhibitor. Previous clinical trials show that antihypertensive treatment with benazepril provides effective blood pressure (BP) control and is generally well tolerated by patients with hypertension. However, the long-term antihypertensive effects and tolerability of benazepril remain to be established in Chinese patients with hypertension.

Objective: The aim of this study was to investigate the long-term efficacy and tolerability of benazepril in Chinese patients with essential hypertension.

Methods: This 36-month, community-based, open-label, postmarketing surveillance study was conducted in the Nanshi District (Shanghai, China). Chinese patients with essential hypertension were to receive 1 or more benazepril tablets PO QD in the morning for 36 months. Data for BP and pulse pressure (PP) were collected at baseline (month 0) and throughout the surveillance period. The rate of patients achieving BP targets (systolic BP [SBP]/diastolic BP [DBP], <140/<90 mm Hg) was determined, as was the rate of decrease in BP. Subanalyses by sex and age group also were conducted.

Results: A total of 1831 patients (1090 men, 741 women; mean [SD] age, 55.8 [10.1] years [range, 35-88 years]) entered the study. After the 36-month treatment period, 75.7% of patients receiving benazepril as prescribed (1289 patients) had achieved the SBP target, 87.4% achieved the DBP target, and 71.5% achieved both targets. After 36 months of treatment, the mean (SD) decreases in SBP, DBP, and PP were 15.1 (0.4) mm Hg, 11.0 (0.3) mm Hg, and 4.2 (0.4) mm Hg, respectively, among compliers. In general, the rate of BP decrease slowed over time. No serious adverse drug reactions (ADRs) were detected during the 36-month follow-up period. All ADRs except cough (19.9%) occurred at a relatively low incidence rate (<3.0%). The cumulative incidence of benazepril-related cough was statistically significantly higher in women than in men (23.6% vs 18.8%, respectively; P = 0.007). Of the 1831 patients studied, 1360 patients (74.3%) persisted in taking benazepril and were considered optimally compliant at 36-month follow-up.

Conclusion: In this study of Chinese patients with hypertension, benazepril was associated with prolonged, stable efficacy in lowering BP and a relatively low incidence of ADRs.

语种英语
WOS记录号WOS:000222748000009
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65953
专题北京大学公共卫生学院
作者单位1.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100083, Peoples R China
2.Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China
3.Nanshi Dist Hlth Off Shanghai, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Lu, J,Lee, LM,Cao, WH,et al. Postmarketing surveillance study of benazepril in Chinese patients with hypertension: An open-label, experimental, epidemiologic study[J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL,2004,65(3):300-319.
APA Lu, J.,Lee, LM.,Cao, WH.,Zhan, SY.,Zhu, GY.,...&Hu, YH.(2004).Postmarketing surveillance study of benazepril in Chinese patients with hypertension: An open-label, experimental, epidemiologic study.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL,65(3),300-319.
MLA Lu, J,et al."Postmarketing surveillance study of benazepril in Chinese patients with hypertension: An open-label, experimental, epidemiologic study".CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL 65.3(2004):300-319.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, J]的文章
[Lee, LM]的文章
[Cao, WH]的文章
百度学术
百度学术中相似的文章
[Lu, J]的文章
[Lee, LM]的文章
[Cao, WH]的文章
必应学术
必应学术中相似的文章
[Lu, J]的文章
[Lee, LM]的文章
[Cao, WH]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。